DTx Pharma, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
DTx Pharma, Inc. - overview
Established
2017
Location
San Diego, CA, US
Primary Industry
Biotechnology
About
Based in California, US, and founded in 2017, DTx Pharma, Inc. operates as a biotechnology company that develops RNA-based therapeutics to treat genetic drivers of diseases. The company was founded by Arthur Suckow, John Grund, and Adam Pavlicek. In July 2023, Novartis acquired DTx Pharma, Inc.
for USD 500 million, including an additional USD 500 million on achievement of pre-specified milestones. The company provides a FALCON platform (Fatty Acid Ligand Conjugated OligoNucleotide) that enables the delivery of RNA therapeutics for neuromuscular diseases. Following the acquisition, Novartis aims to advance the development of DTx Pharma, Inc. 's CMT1A therapeutic program and the FALCON platform.
Current Investors
Tech Coast Angels, Friedman Bioventures, Exsight ventures
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.dtxpharma.com
Company Stage
Acquired
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.